Abstract: An object of the present invention is to provide a method of enabling efficient structural analysis of a target protein that has been impossible or difficult to analyze so far, by stabilizing the target protein. The present invention provides an anti-BRIL antibody which specifically binds to BRIL or a BRIL fusion protein and an antigen-binding fragment thereof, a nucleic acid encoding the anti-BRIL antibody and the antigen-binding fragment thereof, a vector containing the nucleic acid, an antibody producing cell containing the vector, a method of producing the antibody, and a method of using the antibody in a protein structural analysis.
Abstract: The present invention relates to immunoglobulin single variable domains that bind GITR and more in particular to polypeptides that comprise or essentially consist of one or more such immunoglobulin single variable domains; to nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the polypeptides of the present invention enhance the biological activity of GITR.
Type:
Grant
Filed:
October 24, 2016
Date of Patent:
July 13, 2021
Assignee:
Ablynx N.V.
Inventors:
Pieter Deschaght, Sandra Li, Veerle Snoeck, Jan Pype
Abstract: The invention relates to a method for obtaining APRIL-binding peptides. With this method APRIL-binding peptides may be obtained and/or selected. Further aspects of the invention relate to a cell comprising a nucleotide sequence coding for an APRIL-binding peptide according to the invention, a process for producing an APRIL-binding peptide and the APRIL-binding peptide obtainable in the production process and/or the selection method. In view of the possible utility of the APRIL-binding peptides according to the invention, further aspects of the invention relate to diagnostic uses of an APRIL binding peptide of the invention.
Type:
Grant
Filed:
September 11, 2018
Date of Patent:
June 29, 2021
Assignee:
ADURO BIOTECH HOLDINGS, EUROPE B.V.
Inventors:
Hans Van Eenennaam, Andrea Van Elsas, Lilian Driessen, Jan Paul Medema
Abstract: Provided herein are several methods for selecting agents that bind to transmembrane receptors in a conformationally-selective way. In some embodiments, the method may comprise producing: a transmembrane receptor in an active conformation; and said transmembrane receptor in an inactive conformation and using cell sorting to select, from a population of cells comprising a library of cell surface-tethered extracellular capture agents, cells that are specifically bound to either the transmembrane receptor in its active conformation or the transmembrane receptor in its inactive conformation, but not both. In other embodiments, the method may comprise: contacting a GPCR with a population of cells that comprise a library of surface-tethered extracellular proteins; labeling the cell population with a conformationally-specific binding agent, e.g., a G-protein or mimetic thereof; and using cell sorting to select from the cell population cells that bind to the agent.
Type:
Grant
Filed:
November 4, 2019
Date of Patent:
June 22, 2021
Assignee:
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Inventors:
Aaron Michael Ring, Aashish Manglik, Andrew Kruse, Brian K. Kobilka
Abstract: The present disclosure provides hNGAL muteins that bind Ang-2 and can be used in various application including pharmaceutical applications, for example, to inhibit or reduce angiogenesis. The present disclosure also concerns methods of making one or more muteins described herein as well as compositions and combinations comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions and combinations comprising one or more of such muteins.
Type:
Grant
Filed:
November 13, 2019
Date of Patent:
June 15, 2021
Assignee:
Pieris Pharmaceuticals GmbH
Inventors:
Rachida Siham Bel Aiba, Andrea Allersdorfer, Alexander Wiedenmann, Christine Rothe, Shane Olwill, Hendrik Gille, Laurent Audoly
Abstract: Presented herein are novel phosphotyrosine binding compositions, including antibodies and antibody fragments. The inventors of the present disclosure have resolved the crystal structures of two widely utilized pan-specific pY antibodies, PY20 and 4G10. These two known antibodies, although developed independently from animal immunizations, have surprisingly similar modes of recognition of the phosphate group, and revealed a generic binding structure among pan-specific pY antibodies. Based on this newly discovered convergent structure, engineered CDR-L3 loops were developed that impart greatly improved affinity to pY binding antibodies and other pY binding compositions. The inventions disclosed herein include antibodies and antibody fragments bearing these novel CDR-L3 sequences and methods of using such pY binding compositions for the detection of phosphotyrosine-bearing proteins.
Type:
Grant
Filed:
October 30, 2019
Date of Patent:
June 15, 2021
Assignee:
The Regents of the University of California
Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.
Type:
Grant
Filed:
October 25, 2019
Date of Patent:
June 8, 2021
Assignees:
Novartis AG, The Trustees of the University of Pennsylvania
Inventors:
Barbara Brannetti, Jennifer Brogdon, Boris Engels, Brian Walter Granda, Lu Huang, Ming Lei, Na Li, Jimin Zhang, Carla Guimaraes, Saar Gill, Marco Ruella, Regina M. Young
Abstract: An antibody specifically recognizing human tumor necrosis factor 1 (hu TNFR1), for use in treating nonalcoholic steatohepatitis (NASH) and disease conditions associated thereto.
Type:
Grant
Filed:
November 27, 2018
Date of Patent:
June 8, 2021
Assignee:
BALIOPHARMA AG
Inventors:
Heike Bantel, Klaus Pfizenmaier, Andreas Herrmann
Abstract: An antibody-based GnRH receptor antagonist and methods of making and using same are disclosed. The antibody-based GnRH receptor antagonist is a GHR-106 monoclonal antibody (GHR-106) or an antigen-binding fragment thereof. GHR-106 or its IgG fragments can be utilized for therapeutic applications in the treatment of cancer and a range of sex hormone-related disorders or conditions in male or female subjects for which decapeptide GnRH antagonists are currently used.
Abstract: In certain aspects, the present disclosure relates to T?RII fusion polypeptides comprising a heterologous portion and a truncated, ligand-binding portion of the extracellular domain of T?RII polypeptide useful to selectively antagonize a T?RII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGF? associated disorders.
Abstract: The present invention relates to a specific CD95L antibody and to the use thereof in the treatment or diagnosis of diseases involving CD95L-induced signalling, e.g. cancer diseases.
Type:
Grant
Filed:
September 26, 2019
Date of Patent:
May 25, 2021
Assignee:
Apogenix AG
Inventors:
Christian Gieffers, Oliver Hill, Meinolf Thiemann, Jaromir Sykora, Christian Merz, Tim Schnyder, Harald Fricke
Abstract: In certain aspects, the present disclosure relates to polypeptides comprising a truncated, ligand-binding portion of the extracellular domain of T?RII polypeptide useful to selectively antagonize a T?RII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGF? associated disorders.
Type:
Grant
Filed:
January 30, 2020
Date of Patent:
May 18, 2021
Assignee:
ACCELERON PHARMA INC.
Inventors:
Ravindra Kumar, Asya Grinberg, Dianne S. Sako, Roselyne Castonguay, Rita Steeves
Abstract: Biosensors are disclosed for detecting ligand binding at ectopic Olfactory Receptors. Methods of identifying novel ectopic Olfactory Receptors are also disclosed. Ligands for ectopic Olfactory Receptors are disclosed as well as methods for using these ligands to interact with ectopic Olfactory Receptors, including the use of such ligands in the treatment and/or mitigation of disease conditions.
Abstract: The present disclosure provides binding proteins, such as antibodies, that bind glucagon receptors, including a human glucagon receptor, and methods of their use.
Type:
Grant
Filed:
January 26, 2018
Date of Patent:
May 4, 2021
Assignee:
NGM Biopharmaceuticals, Inc.
Inventors:
Wenyan Shen, Yan Wang, Hugo Matern, Zhonghao Liu
Abstract: Inhibition of the expression and/or function of nicotinamide phosphoribosyltransferase (NAMPT) can reduce, prevent or reverse the pathophysiological vascular changes associated with the onset and progression of Pulmonary Fibrosis. Compositions and methods to inhibit the expression and function of NAMPT for treating and preventing Pulmonary Fibrosis in a subject in need are provided. The compositions and methods are useful for the modulation of pathophysiological processes that contribute to the development and progression of Pulmonary Fibrosis by reducing lung inflammation, aberrant myofibroblast accumulation and deposition of collagen in fibrotic foci.
Type:
Grant
Filed:
April 16, 2018
Date of Patent:
May 4, 2021
Assignees:
Arizona Board of Regents on Behalf of The University of Arizona, The United States of America as Represented by the Department of Veterans Affairs
Abstract: The composition of anti-TNFR2 antibodies are provided, as well as methods of their preparation and use. This includes methods for treating disorders associated with TNF and/or TNFR2, such as cancer.
Abstract: In certain aspects, the present disclosure relates to polypeptides comprising a truncated, ligand-binding portion of the extracellular domain of T?RII polypeptide useful to selectively antagonize a T?RII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGF? associated disorders.
Type:
Grant
Filed:
April 24, 2019
Date of Patent:
April 20, 2021
Assignee:
ACCELERON PHARMA INC.
Inventors:
Ravindra Kumar, Asya Grinberg, Dianne S. Sako, Roselyne Castonguay, Rita Steeves
Abstract: The disclosure relates to novel uses and methods for preventing and/or treating heart disease, which employ a therapeutically effective amount of an ActRII receptor antagonist, e.g., an ActRII receptor binding molecule, e.g., an ActRII receptor antibody, such as the bimagrumab antibody.
Type:
Grant
Filed:
March 20, 2018
Date of Patent:
April 20, 2021
Assignees:
Novartis AG, Beth Israel Deaconess Medical Center, Inc.
Inventors:
Anthony Rosenzweig, Jason D. Roh, David J. Glass
Abstract: Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy.
Type:
Grant
Filed:
June 25, 2020
Date of Patent:
April 20, 2021
Assignee:
VISTERRA, INC.
Inventors:
James R. Myette, Zachary Holmes Shriver, Karthik Viswanathan, Andrew M. Wollacott, Hedy Adari-Hall, Boopathy Ramakrishnan, Gregory Babcock